Gennaro Colella

Gennaro Colella

Auto-generated profile, based on publicly available information

Gennaro Colella

Experimental Oncology and Pharmacogenomics, IRCCS Fondazione "Salvatore Maugeri"-Istituto di Pavia, Pavia, Italy

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2002 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
Nadia ZaffaroniNadia Zaffaroni
Nadia Zaffaroni
MPM. Pennati
M. Pennati
GCG. Colella
G. Colella
Paola PeregoPaola Perego
Paola Perego
RSR. Supino
R. Supino
MDMaria Grazia Daidone
Maria Grazia Daidone

14 February 2011 in Cancer Research
Verified
Journal Article
Closed access
EBEzia Bello
Ezia Bello
GCGennaro Colella
Gennaro Colella
VSValentina Scarlato
Valentina Scarlato
POPaolo Oliva
Paolo Oliva
ABAlexander Berndt
Alexander Berndt
GCGabriella Camboni
Gabriella Camboni
Tumor angiogenesis is a degenerate process regulated by a complex network of proangiogenic factors. Existing antiangiogenic drugs used in clinic are characterized by selectivity for specific factors. Antiangiogenic properties might be improved in drugs that target multiple factors and thereby address the inherent mechanistic degeneracy in angiogenesis. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) family members and their cognate receptors are key players in promoting tumor angiogenesis. Here we report the pharmacologic profile of E-3810, a novel dual inhibitor of the VEGF and FGF receptors. E-3810 potently and selectively inhibited VEGF receptor (VEGFR)-1, -2, and -3 and FGF receptor (FGFR)-1 and -2 kinases in the nanomolar range. Ligand-dependent phosphorylation of VEGFR-2 and FGFR-1 was suppressed along with human vascular endothelial cell growth at nanomolar concentrations. In contrast, E-3810 lacked cytotoxic effects on cancer cell lines under millimolar concentrations. In a variety of tumor xenograft models, including early- or late-stage subcutaneous and orthotopic models, E-3810 exhibited striking antitumor properties at well-tolerated oral doses administered daily. We found that E-3810 remained active in tumors rendered nonresponsive to the general kinase inhibitor sunitinib resulting from a previous cycle of sunitinib treatment. In Matrigel plug assays performed in nude mice, E-3810 inhibited basic FGF–induced angiogenesis and reduced blood vessel density as assessed by histologic analysis. Dynamic contrast-enhanced magnetic resonance imaging analysis confirmed that E-3810 reduced the distribution of angiogenesis-sensitive contrast agents after only 5 days of treatment. Taken together, our findings identify E-3810 as a potent antiangiogenic small molecule with a favorable pharmacokinetic profile and broad spectrum antitumor activity, providing a strong rationale for its clinical evaluation. Cancer Res; 71(4); 1396–405. ©2011 AACR.

1 April 2003 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MPMarzia Pennati
Marzia Pennati
MBMara Binda
Mara Binda
GCGennaro Colella
Gennaro Colella
Marco FoliniMarco Folini
Marco Folini
RVRaffaella Villa
Raffaella Villa
LCLorenzo Citti
Lorenzo Citti


1 February 2000 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
Marco FoliniMarco Folini
Marco Folini
GCGennaro Colella
Gennaro Colella
RVRaffaella Villa
Raffaella Villa
SLSusanna Lualdi
Susanna Lualdi
MDMaria Grazia Daidone
Maria Grazia Daidone
Nadia ZaffaroniNadia Zaffaroni
Nadia Zaffaroni

1 February 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
EBEzia Bello
Ezia Bello
GTGiulia Taraboletti
Giulia Taraboletti
GCGennaro Colella
Gennaro Colella
MZMassimo Zucchetti
Massimo Zucchetti
DFDaniele Forestieri
Daniele Forestieri
Giovanna DamiaGiovanna Damia
Giovanna Damia
E-3810 is a novel small molecule that inhibits VEGF receptor-1, -2, and -3 and fibroblast growth factor receptor-1 tyrosine kinases at nmol/L concentrations currently in phase clinical II. In preclinical studies, it had a broad spectrum of antitumor activity when used as monotherapy in a variety of human xenografts. We here investigated the activity of E-3810 combined with different cytotoxic agents in a MDA-MB-231 triple-negative breast cancer xenograft model. The molecule could be safely administered with 5-fluorouracil, cisplatin, and paclitaxel. The E-3810–paclitaxel combination showed a striking activity with complete, lasting tumor regressions; the antitumor activity of the combination was also confirmed in another triple-negative breast xenograft, MX-1. The activity was superior to that of the combinations paclitaxel+brivanib and paclitaxel+sunitinib. Pharmacokinetics studies suggest that the extra antitumor activity of the combination is not due to higher paclitaxel tumor levels, which in fact were lower in mice pretreated with all three kinase inhibitors, and the paclitaxel plasma levels excluded reduced drug availability. Pharmacodynamic studies showed that E-3810, brivanib, and sunitinib given as single agents or in combination with paclitaxel reduced the number of vessels, but did not modify vessel maturation. Reduced tumor collagen IV and increased plasma collagen IV, associated with increased matrix metalloproteinases (MMP), particularly host MMP-9, indicate a proteolytic remodeling of the extracellular matrix caused by E-3810 that in conjunction with the cytotoxic effect of paclitaxel on the tumor cells (caspase-3/7 activity) may contribute to the striking activity of their combination. These data support the therapeutic potential of combining E-3810 with conventional chemotherapy. Mol Cancer Ther; 12(2); 131–40. ©2012 AACR.